These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12003185)

  • 1. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
    Whitehead RP; Unger JM; Flaherty LE; Kraut EH; Mills GM; Klein CE; Chapman RA; Doolittle GC; Hammond N; Sondak VK;
    Invest New Drugs; 2002 Feb; 20(1):105-11. PubMed ID: 12003185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
    Whitehead RP; Unger JM; Flaherty LE; Eckardt JR; Taylor SA; Didolkar MS; Samlowski W; Sondak VK
    Invest New Drugs; 2001; 19(3):239-43. PubMed ID: 11561681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
    Vogelzang NJ; Mani S; Schilsky RL; Ansari RH; Taber D; Rhinehart SN; Garcia JC; Meyer SC; Mick R; Brockstein BE; Stadler WM; Ratain MJ; Vokes EE
    Clin Cancer Res; 1998 Apr; 4(4):929-34. PubMed ID: 9563886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
    Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
    Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
    Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
    Dhodapkar MV; Richardson RL; Reid JM; Ames MM
    Invest New Drugs; 1994; 12(3):207-16. PubMed ID: 7896539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
    Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
    Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer.
    Edelman MJ; Meyers FJ; Grennan T; Lauder J; Doroshow J
    Invest New Drugs; 1998; 16(2):179-82. PubMed ID: 9848583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
    Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
    Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
    Sosman JA; Flaherty LE; Liu PY; Fletcher W; Thompson JA; Hantel A; Sondak V
    Invest New Drugs; 1995; 13(1):83-7. PubMed ID: 7499114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study.
    Slavik M; Kopecky KJ; Sondak V; Craig JB; Samson MK
    Invest New Drugs; 1993; 11(2-3):223-6. PubMed ID: 8262736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pyrazine diazohydroxide (NSC 361456) for advanced non small-cell lung cancer.
    Blackstock AW; Acostamadiedo J; Lesser G; Richards F; Case LD; White DR
    Clin Lung Cancer; 2000 Aug; 2(1):62-6. PubMed ID: 14731342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study.
    Whitehead RP; Unger JM; Goodwin JW; Walker MJ; Thompson JA; Flaherty LE; Sondak VK
    J Immunother; 1998 Nov; 21(6):440-6. PubMed ID: 9807739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
    Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
    Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog.
    Moore DJ; Brodfuehrer JI; Wilke TJ; Powis G
    Cancer Chemother Pharmacol; 1988; 21(4):269-73. PubMed ID: 3370734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of fotemustine in patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    Invest New Drugs; 1994; 12(3):251-4. PubMed ID: 7896545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
    Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
    Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.